{
    "nct_id": "NCT06297525",
    "official_title": "An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer",
    "inclusion_criteria": "* Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.\n* Male or female aged ≥ 18 years.\n* Advanced disease not curable by available therapies and requires systemic therapy.\n* Histologically confirmed diagnosis of eligible cancer type.\n* Must have tumor tissue available for biomarker testing.\n* Measurable disease (Part 1) and measurable disease per RECIST (Part2)\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Life expectancy > 3 months as assessed by the Investigator.\n* Adequate organ function (bone marrow, hepatic, renal function and coagulation).\n* All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment.\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or breastfeeding females and women of childbearing potential or males unwilling to comply with contraception requirements.\n* Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease or a history of spinal cord compression\n* Active malignancy within 2 years of study enrollment\n* Prior radiation within 2 weeks of start of therapy.\n* Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or <5 half-lives since completion of previous investigational therapy, whichever is shorter.\n* Uncontrolled intercurrent illness.\n* Immunocompromised subjects with increased risk of opportunistic infections or history of opportunistic infection in the last 12 months.\n* Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.\n* Subjects with corrected QT interval >470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).",
    "miscellaneous_criteria": "Main"
}